ReviewMicroorganisms2023
Microbiome in Cancer Development and Treatment.
Review in Microorganisms, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- ZNF750 suppresses esophageal squamous cell carcinoma by maintaining epithelial barrier-driven mucosal immune homeostasis.Biology direct · 2026Article
- Long-Term Clinical Consequences of Severe Oral Mucositis in Survivors of Lip, Oral Cavity, and Pharynx Cancer Versus Leukemia: A Propensity-Score-Matched Comparative Cohort Study Using Real-World Data.Medical sciences (Basel, Switzerland) · 2026Article
- Trehalose Exerts Selective Cytotoxicity Against Tongue Squamous Cell Carcinoma Cells While Exhibiting Limited Cytotoxicity Toward Normal Oral Squamous Cells.OncoTargets and therapy · 2026Article
- Microbiome-Driven Mechanisms in Breast Cancer: Emerging Evidence From Gut Microbial Signatures to Therapeutic Response.BioMed research international · 2026Review
- Gut Microbiota-Immune Interactions in Endometrial Cancer: Causal Mediation and Subtype-Specific Mechanisms.International journal of women's health · 2026Article
- Gut microbiome and chemotherapy-induced cardiotoxicity: A systematic review of evidence and emerging therapies.World journal of biological chemistry · 2025Article
- Ginseng Polysaccharides InhibitCancers · 2025Article
- The microbiome-cancer axis as a hidden contributor to early-onset tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- Review
- Molecular Mechanisms of Probiotic Action Against Gastrointestinal Cancers.International journal of molecular sciences · 2025Review
- Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.Biomedicines · 2025Review
- Resveratrol Alleviated Intensive Exercise-Induced Fatigue Involving in Inhibiting Gut Inflammation and Regulating Gut Microbiota.Food science & nutrition · 2025Article
- The Effect of Microbiome-Derived Metabolites in Inflammation-Related Cancer Prevention and Treatment.Biomolecules · 2025Review
- Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.NPJ biofilms and microbiomes · 2025Review
- Molecular mechanisms and therapeutic strategies of gut microbiota modulation in Sarcopenia (Review).Oncology letters · 2025Review
- Microbiome Integrity Enhances the Efficacy and Safety of Anticancer Drug.Biomedicines · 2025Review
- Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors.Cancers · 2024Review
- The Link Between the Gut Microbiome and Bone Metastasis.International journal of molecular sciences · 2024Review
- Exploring the microbiome-gut-testis axis in testicular germ cell tumors.Frontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Targeting the microbiome, microbiota-derived metabolites, and related pathways represents a significant challenge in oncology. Microbiome analyses have confirmed the negative impact of cancer treatment on gut homeostasis, resulting in acute dysbiosis and severe complications, including massive inflammatory immune response, mucosal barrier disruption, and bacterial translocation across the gut epithelium. Moreover, recent studies revealed the relationship between an imbalance in the gut microbiome and treatment-related toxicity. In this review, we provide current insights into the role of the microbiome in tumor development and the impact of gut and tumor microbiomes on chemo- and immunotherapy efficacy, as well as treatment-induced late effects, including cognitive impairment and cardiotoxicity. As discussed, microbiota modulation via probiotic supplementation and fecal microbiota transplantation represents a new trend in cancer patient care, aiming to increase bacterial diversity, alleviate acute and long-term treatment-induced toxicity, and improve the response to various treatment modalities. However, a more detailed understanding of the complex relationship between the microbiome and host can significantly contribute to integrating a microbiome-based approach into clinical practice. Determination of causal correlations might lead to the identification of clinically relevant diagnostic and prognostic microbial biomarkers. Notably, restoration of intestinal homeostasis could contribute to optimizing treatment efficacy and improving cancer patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.